Abstract: A D-galactopyranose compound of formula (1) wherein the pyranose ring is beta-D-galactopyranose, and these compounds are high affinity galectin-1 and/or 3 inhibitors for use in treatment of a disorder relating to the binding of a galectin-1 and/or 3 to a ligand in a mammal.

Abstract: A compound of the general formula (1). The compound of formula (1) is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human. Also, a method for treatment of a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human.

Abstract: An embodiment of the present invention relates to a compound of the general formula. The compound of formula is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human. Furthermore an embodiment of the present invention concerns a method for treatment of a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human.

Abstract: A D-galactopyranose compound of formula (1) wherein the pyranose ring is beta-D-galactopyranose, and these compounds are high affinity galectin-1 and/or 3 inhibitors for use in treatment of inflammation; fibrosis; scarring; keloid formation; aberrant scar formation; surgical adhesions; scleroderma; systemic sclerosis; septic shock; cancer; metastasising cancers; autoimmune diseases; metabolic disorders; heart disease; heart failure; aortic stenosis; atherosclerosis; pathological angiogenesis; eye diseases; metabolic diseases; insulin resistance; obesity; Diastolic HF; asthma; otosclerosis; mesothelioma; liver disorders Liver cancer; cholangiocarcinoma; biliary tract cancer; and neurodegenerative disorders.

Abstract: An ?-D-galactopyranose compound of the general formula (1). The ?-D-galactopyranose compound of formula (1) is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-1 to a ligand in a mammal, such as a human. Furthermore, a method for treatment of a disorder relating to the binding of a galectin, such as galectin-1 to a ligand in a mammal, such as a human.

Abstract: A process for preparing a compound of formula (X) The process includes reacting a compound of formula (IX) with an acetylating agent in the presence of a base in a suitable solvent and at a suitable temperature for a sufficient reaction time for preparing the compound of formula X. The process is suitable for large scale synthesis.

Abstract: A process for preparing a compound of formula (I) wherein the process is suitable for large scale synthesis. The process includes the consecutive steps of a) reacting a compound of formula IX and a catalyst and optionally adding a base in an organic solvent and optional adding a basic fluoride source agent under suitable conditions to obtain a compound of formula X and b) removing the protective groups of the compound X to obtain the compound formula (I).

Abstract: The present invention relates to a D-galactopyranose compound of formula (1) wherein the pyranose ring is ?-D-galactopyranose, and these compounds are high affinity galectin-1 and/or galectin 3 inhibitors for use in treatment of inflammation; fibrosis; scarring; keloid formation; aberrant scar formation; surgical adhesions; septic shock; cancer; metastasising cancers; autoimmune diseases, metabolic disorders; heart disease; heart failure; pathological angiogenesis; eye diseases; atherosclerosis; metabolic diseases; diabetes type I; diabetes type II; insulin resistance; Diastolic heart failure; asthma; liver disorders.

Abstract: A compound of the general formula (1). The compound of formula (1) is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human. Also, a method for treatment of a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human.

Abstract: A compound of the general formula (1). The compound of formula (1) is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human. Also, a method for treatment of a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human.

Abstract: An embodiment of the present invention relates to a compound of the general formula. The compound of formula is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human. Furthermore an embodiment of the present invention concerns a method for treatment of a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human.

Abstract: A D-galactopyranose compound of formula (1) wherein the pyranose ring is ?-D-galactopyranose, and these compounds are high affinity galectin-3 inhibitors. Also, pharmaceutical compositions including these compounds. Further, a method for treatment of a disorder relating to the binding of a galectin-3 to a ligand, such as inflammation, in a mammal, such as a human, wherein a therapeutically effective amount of at least one of these compounds is administered to a mammal in need of the treatment.

Abstract: A compound of formula (I) for use in a method for treatment of pulmonary fibrosis in a human including administering, with a dry powder inhaler, once-a-day to the narrowest parts of the lung tissue of the human an amount of the compound of formula (I) effective to treat the pulmonary fibrosis.

Abstract: A D-galactopyranose compound of formula (1) wherein, the pyranose ring is beta-D-galactopyranose, and pharmaceutical composition including these compounds. These are high affinity galectin-1 and/or 3 inhibitors. Also, methods for treating a disorder relating to the binding of a galectin-1 and/or -3 to a ligand in which these compounds or pharmaceutical compositions are administered.

Abstract: The present invention relates to a process for preparing a compound of formula (I) wherein said process is suitable for large scale synthesis.

Abstract: The present invention relates to a compound of formula (I) for use in a method for treatment of pulmonary fibrosis in a human including administering once-a-day to the narrowest parts of the lung tissue of the human an amount of the compound of formula (I) effective to treat said pulmonary fibrosis.

Abstract: An embodiment of the present invention relates to a compound of the general formula. The compound of formula is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human. Furthermore an embodiment of the present invention concerns a method for treatment of a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human.

Abstract: A stabilized amorphous form of a compound of formula I as well as compositions for oral administration including the compound of formula I in a therapeutically effective amount. Also, methods for treatment of a disease or disorder in which therapeutically effective amount of a composition including a compound of formula I is administered to a subject in need thereof.

Abstract: A compound of the general formula (1). The compound of formula (1) is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human. Also, a method for treatment of a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human.

Abstract: A prodrug compound of the general formula I or II. The prodrug compound of formula I or II is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human. Also, a method for treatment of a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human.